Image 8_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Image 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Table 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Table 2_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Table 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Table 1_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Image 7_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Table 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Table 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Image 6_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Image 3_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

“…Background<p>Previous research has confirmed that integrating PD-1/PD-L1 inhibitors with chemotherapy (PC) represents a more effective strategy for treating advanced non-small-cell lung cancer (NSCLC). …”

Supplementary Material for: Temporal trends of pediatric stroke burden attributable to non-optimal temperature in the United States, 1990-2019: An analysis for the Global Burden of... by figshare admin karger (2628495)

“…Introduction: Pediatric stroke, though less common than in the elderly population, imposes a significant societal burden. With the increasing impact of climate change, this study aimed to assess the burden of different pediatric stroke subtypes attributable to non-optimal temperatures in the United States and estimate future trends. …”

Numerical data underlying the graphs. by Stephanie M. E. Jones (12883691)

“…MITF and c-MYC, key melanoma transcription factors, regulate human <i>DANCR</i> expression and melanoma patients with high <i>DANCR</i> display significantly decreased survival. <i>DANCR</i> is a melanoma oncogene that controls cancer-associated gene expression networks to promote human melanoma cell proliferation and migration. …”

Sequence of oligonucleotides used in this study. by Stephanie M. E. Jones (12883691)

“…MITF and c-MYC, key melanoma transcription factors, regulate human <i>DANCR</i> expression and melanoma patients with high <i>DANCR</i> display significantly decreased survival. <i>DANCR</i> is a melanoma oncogene that controls cancer-associated gene expression networks to promote human melanoma cell proliferation and migration. …”

<i>DANCR</i> regulated genes in SK-MEL-28 cells. by Stephanie M. E. Jones (12883691)

“…MITF and c-MYC, key melanoma transcription factors, regulate human <i>DANCR</i> expression and melanoma patients with high <i>DANCR</i> display significantly decreased survival. <i>DANCR</i> is a melanoma oncogene that controls cancer-associated gene expression networks to promote human melanoma cell proliferation and migration. …”

Table 1_Comparative study of endophytic bacterial strains from non-host crops for enhancing plant growth and managing early blight in tomato.docx by Aditya Kukreti (20129547)

“…However, comparative studies of these endophytes in vitro and in planta in non-host crops are lacking. Therefore, in this study, we evaluated the potential of endophytes B. pseudomycoides strain HP3d, P. polymyxa strain PGSS1, B. velezensis strain A6, and P42, isolated from various crop ecosystems in promoting plant growth and inducing systemic resistance against early blight disease in tomato. …”

Data_Sheet_1_Systematic analysis and prediction of the burden of lower respiratory tract infections attribute to non-optimal temperature, 1990–2019.docx by Yu Shi (117923)

“…Background<p>Lower respiratory infections (LRIs) remain one of the most deadly infectious diseases in the world, and non-optimal temperature is a risk factor for LRIs. …”

Data Sheet 1_Non-targeted metabolomics-mediated elucidation of metabolite changes in Polygonatum kingianum during traditional steaming with black beans.zip by Haiyan Zhu (110483)

“…Compared to the raw PK, the P3 stage exhibited significant increases in saponins, total sugars, organic acids, and flavonoids by 21.29, 35.02, 49.13, and 44.76%, respectively (p < 0.05), reducing sugars showed a remarkable increase of 160.94-fold (p < 0.01), while polysaccharides decreased significantly by 43.33% (p < 0.01).…”

Variability in performance and response to task dynamics. by Daniel Ramandi (10047543)

“…(B) The analysis of trajectory variability, quantified as DTW distance of consecutive trials, showed a non-significant trend towards greater variability in zQ175 mice, peaking later compared to WT mice (RM two-way ANOVA, genotype p = 0.070 F(1, 20) = 3.660, trial p = 0.0005 F(4.291, 85.82) = 5.351, interaction p = 0.542 F(19, 380) = 0.9329). …”

Genotoxic Mechanisms of Erythrophleum suaveolens Stem Bark Extracts and Fractions in MCF-7 Breast Cancer Cells via Mitochondrial and Non-Mitochondrial Pathways by Lateef Sulaimon (21706283)

“…After 72 hours, ESSB-treated MCF-7 cells showed a significant (p < 0.05) increase in DNA fragmentation and comet tail DNA percentages (flavonoids induced a 1.21-fold increase in comet tail length). …”